Literature DB >> 2661160

New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6.

N Kohno1, S Kyoizumi, Y Awaya, H Fukuhara, M Yamakido, M Akiyama.   

Abstract

Serum levels of a high molecular weight circulating antigen KL-6, detected by means of a sandwich assay using a monoclonal antibody KL-6 against a sialylated carbohydrate antigen, were evaluated for usefulness in monitoring the activity of interstitial pneumonitis. Abnormally high levels of KL-6 antigen were observed in the sera of 34 (58 percent) of 59 patients with interstitial pneumonitis. There was no significant correlation between serum values of KL-6 antigen and LDH activity. There was a positive correlation between KL-6 antigen levels and the degree of clinical disease activity as measured by 67Ga-citrate scintigram and the clinical course. Though this is a preliminary study, these observations suggest that the serum level of KL-6 antigen may be a useful indicator of disease activity in patients with interstitial pneumonitis. It does not appear to be useful, however, in the differential diagnosis of interstitial pneumonitis from malignant and nonmalignant diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2661160     DOI: 10.1378/chest.96.1.68

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  104 in total

1.  Serum KL-6 levels in patients with pulmonary complications after allogeneic bone marrow transplantation.

Authors:  T Ashida; M Higashishiba; Y Sumimoto; T Sano; H Miyazato; T Shimada; J Miyatake; K Kawanishi; Y Tatsumi; A Kanamaru
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

2.  Serum KL-6, a novel mucin-like glycoprotein, as an indicator of interstitial pneumonitis following lobectomy.

Authors:  T Sakuma; K Takahashi; N Ohya; K Usuda; M Handa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

3.  Increased expression of mucinous glycoprotein KL-6 in human pterygium.

Authors:  S Kase; N Kitaichi; N Furudate; K Yoshida; S Ohno
Journal:  Br J Ophthalmol       Date:  2006-09       Impact factor: 4.638

4.  Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.

Authors:  Tomoo Kishaba; Hiroaki Nagano; Yuichiro Nei; Shin Yamashiro
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

Review 5.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

Review 6.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

7.  Circulating KL-6 levels in patients with drug induced pneumonitis.

Authors:  H Ohnishi; A Yokoyama; Y Yasuhara; A Watanabe; T Naka; H Hamada; M Abe; K Nishimura; J Higaki; J Ikezoe; N Kohno
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

8.  Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias.

Authors:  Yuji Ohtsuki; Norihiko Nakanishi; Jiro Fujita; Takeo Yoshinouchi; Makoto Kobayashi; Nobuo Ueda; Gang-Hong Lee; Mutsuo Furihata
Journal:  Med Mol Morphol       Date:  2007-09-18       Impact factor: 2.309

9.  Increase of KL-6 in sera of uveitis patients with sarcoidosis.

Authors:  Nobuyoshi Kitaichi; Satoshi Kotake; Hitoshi Shibuya; Yukiho Yamada; Hitoshi Chiba; Kenichi Namba; Shigeaki Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-11       Impact factor: 3.117

10.  Increased blood carboxyhaemoglobin concentrations in inflammatory pulmonary diseases.

Authors:  H Yasuda; M Yamaya; M Yanai; T Ohrui; H Sasaki
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.